Title Novartis launches rivastigmine patches for mild to moderately severe Alzheimer’s dementia
Date Published 22/10/2007
Reporter initials Hina
Reporter surname Radia
Reporter affiliation Hospital Pharmacist
Source Personal communication, Novartis Pharmaceuticals, 19 October 2007
Abstract Novartis Pharmaceuticals has announced the launch of rivastigmine (Exelon) patches licensed for the symptomatic treatment of mild to moderately severe Alzheimer’s dementia.
The following patch strengths are available:
• Exelon 4.6 mg/24 h; 30 patches – basic NHS cost = £83.84
• Exelon 9.5 mg/24 h; 30 patches – basic NHS cost = £83.84
22 octubre 2007
Dehydrodidemnin B ( Aplidin , Plitidepsin ) Patente US .
Dehydrodidemnin B
Publication number: USRE39887E
Publication date: 2007-10-16
Inventor: RINEHART KENNETH L (US); LITHGOW-BERTELLONI ANNA M (ES)
Applicant: PHARMA MAR SA (ES)
Classification:
- international: C07K7/00; C07K7/00;
- European:
Application number: US20050145507 20050602
Priority number(s): GB19890022026 19890929; US19940280110 19940725; WO1990GB01495 19901001; US20050145507 20050602
Abstract of USRE39887E
Dehydrodidemnin B with useful biological activity has formula (1). It can be isolated from natural sources or synthesized, and it forms active derivativ
Suscribirse a:
Entradas (Atom)